deltatrials
Completed PHASE3 NCT00002556

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

The Treatment of Multiple Myeloma Utilizing VBMCP Chemotherapy Alternating With High-Dose Cyclophosphamide and Alpha2b-Interferon Versus VBMCP: A Phase III Study for Previously Untreated Multiple Myeloma

Sponsor: National Cancer Institute (NCI)

Conditions Stage I Multiple Myeloma Stage II Multiple Myeloma Stage III Multiple Myeloma
Interventions carmustine cyclophosphamide laboratory biomarker analysis melphalan prednisone recombinant interferon alfa-2b vincristine sulfate
Updated 6 times since 2017 Last updated: May 30, 2013 Started: Jul 31, 1994 Primary completion: Jan 31, 2006

This PHASE3 trial investigates Stage I Multiple Myeloma and Stage II Multiple Myeloma and is currently completed. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 1994 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jul 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States